The clinical utility of the Khorana score in determining risk for venous thromboembolism in patients with gynecologic cancer

Apple, Annie; Prescott, Lauren S.; Robinson, Marc; Shultes, Kendall C.; Brown, Alaina J.

doi:10.1016/s0090-8258(21)01200-2

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients with KS ≥ 3 (high-risk) had a VTE incidence of 30%, while the ones with KS = 1–2 (intermediate risk) had a disease incidence of 10%, which is somewhat comparable to the results of a previous study among patients with gynaecological tumours 45 . Also following the literature, the original cut-off score (≥ 3) seems to be more appropriate to determine VTE risk among these patients 46 . Although out of the scope of this study, KS ≥ 3 was found to predict a worse prognosis (≥ 3 vs. < 3, log-rank test, P = 0.046).…”

Section: Discussionmentioning

confidence: 96%

Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer

Neto

Tavares

Silva

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a leading cause of death among cancer patients. Khorana score (KS) is the most studied tool to predict cancer-related VTE, however, it exerts poor sensitivity. Several single-nucleotide polymorphisms (SNPs) have been associated with VTE risk in the general population, but whether they are predictors of cancer-related VTE is a matter of discussion. Compared to other solid tumours, little is known about VTE in the setting of cervical cancer (CC) and whether thrombogenesis-related polymorphisms could be valuable biomarkers in patients with this neoplasia. This study aims to analyse the effect of VTE occurrence on the prognosis of CC patients, explore the predictive capability of KS and the impact of thrombogenesis-related polymorphisms on CC-related VTE incidence and patients’ prognosis regardless of VTE. A profile of eight SNPs was evaluated. A retrospective hospital-based cohort study was conducted with 400 CC patients under chemoradiotherapy. SNP genotyping was carried on by using TaqMan® Allelic Discrimination methodology. Time to VTE occurrence and overall survival were the two measures of clinical outcome evaluated. The results indicated that VTE occurrence (8.5%) had a significant impact on the patient’s survival (log-rank test, P < 0.001). KS showed poor performance (KS ≥ 3, χ2, P = 0.191). PROCR rs10747514 and RGS7 rs2502448 were significantly associated with the risk of CC-related VTE development (P = 0.021 and P = 0.006, respectively) and represented valuable prognostic biomarkers regardless of VTE (P = 0.004 and P = 0.010, respectively). Thus, thrombogenesis-related genetic polymorphisms may constitute valuable biomarkers among CC patients allowing a more personalized clinical intervention.

show abstract

Section: Discussionmentioning

confidence: 96%